INTRODUCTION
Hyperhidrosis (HH) is a disorder of eccrine sweat production in an amount in excess of what is needed for thermoregulation. It is estimated that HH affects 4.8% of the US population or about 15.3 million people and produces a significant impact on quality of life.1-4
Glycopyrronium tosylate cloth (GC) (QBREXZA® Journey Medical Corporation, Scottsdale, Arizona) is a topical anticholinergic approved in the U.S. in 2018 for treatment of primary axillary hyperhidrosis in patients ≥9 years.5-7 In an algorithm for treatment of primary axillary hyperhidrosis developed by the International Hyperhidrosis Society, GC and topical antiperspirants are recommended as first-line treatment.8 Clinicians often use GC off-label to treat body areas other than the axilla, especially the palms, but there is no published guidance on efficacy, safety, or optimal method of palmar applications. Oral anticholinergics are commonly used off-label to treat hyperhidrosis of the palms and other body areas, but their utility is often limited by anticholinergic adverse effects, such as dry mouth and blurred vision, which can occur at doses required for efficacy.9
The purpose of this study was to compare four different methods of palmar application of GC using Patient-Reported Outcomes (PRO’s) to determine if a difference in efficacy and/or safety could be determined with different methods of application. There was no placebo-control group, and there were no statistical analyses performed, so determination of the true efficacy for treatment of palmar HH with GC was not the purpose of and cannot be determined by this study.
Study Design and Subject Selection
One hundred twenty subjects, age nine years or older, with self-reported excessive sweating of the palms, who met the
Glycopyrronium tosylate cloth (GC) (QBREXZA® Journey Medical Corporation, Scottsdale, Arizona) is a topical anticholinergic approved in the U.S. in 2018 for treatment of primary axillary hyperhidrosis in patients ≥9 years.5-7 In an algorithm for treatment of primary axillary hyperhidrosis developed by the International Hyperhidrosis Society, GC and topical antiperspirants are recommended as first-line treatment.8 Clinicians often use GC off-label to treat body areas other than the axilla, especially the palms, but there is no published guidance on efficacy, safety, or optimal method of palmar applications. Oral anticholinergics are commonly used off-label to treat hyperhidrosis of the palms and other body areas, but their utility is often limited by anticholinergic adverse effects, such as dry mouth and blurred vision, which can occur at doses required for efficacy.9
The purpose of this study was to compare four different methods of palmar application of GC using Patient-Reported Outcomes (PRO’s) to determine if a difference in efficacy and/or safety could be determined with different methods of application. There was no placebo-control group, and there were no statistical analyses performed, so determination of the true efficacy for treatment of palmar HH with GC was not the purpose of and cannot be determined by this study.
Study Design and Subject Selection
One hundred twenty subjects, age nine years or older, with self-reported excessive sweating of the palms, who met the
